Home
NewsNewsLuna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
On March 17, 2026, healthtech innovator Luna and fertility benefits provider Kindbody announced a strategic partnership aimed at transforming women’s health through enhanced data-driven Intelligence in Fertility Care. This collaboration is designed to provide unprecedented clarity and personalisation for individuals navigating the complexities of the fertility journey.
Luna, recognised for developing advanced smart wearables, will integrate its biomarker tracking technology into Kindbody’s comprehensive fertility and family-building platform. This integration addresses a critical gap in reproductive health: the fact that intricate physiological shifts, such as changes in temperature, recovery, sleep, stress, and hormonal rhythms, primarily occur outside of a doctor's office. By bringing these daily signals into focus, the partnership offers patients a deeper understanding of their own bodies while providing Kindbody’s clinical teams with a contextual, holistic view of each individual’s health.
Amit Khatri, Founder of Luna, emphasised the human element of this technological advancement. “The conception journey is one of the most meaningful and complex chapters in a person's life, and it deserves both deep empathy and deep intelligence,” said Khatri. “By uniting Luna's continuous biomarker sensing with Kindbody's world-class clinical expertise, we are giving patients a clearer window into their bodies and giving physicians a new dimension of insight that can elevate the entire care experience. This partnership represents the future of reproductive health: connected, personalised, and profoundly human."
Kindbody, which operates a national network of signature clinics and provides virtual care, offers a wide array of services, including IVF, egg freezing, donor care, and LGBTQ+ fertility support. The company’s mission is to make high-quality reproductive care more accessible and equitable. Through this partnership, Luna’s technology, including the Luna ring, will be made available within the Kindbody ecosystem to support patients seeking a more connected path toward parenthood.
David Stern, CEO of Kindbody, highlighted the clinical value of the collaboration. “This partnership with Luna represents a significant step forward in making fertility care smarter and more personalised," said Stern. “By leveraging data-driven insights, we can better support patients and providers alike, ensuring every decision is informed, effective, and centred on the needs of those on their fertility journey."
At the heart of Luna’s contribution is LifeOS, an adaptive health operating system that interprets data from the Luna Ring to deliver real-time guidance on energy, recovery, and women’s health. Kindbody continues to expand its reach, offering benefit solutions for employers and health plans while covering everything from menopause to male fertility and holistic well-being. Together, the two companies aim to move precision health from an aspirational concept to a standard of care.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
